Substituted chromanes and method of use

Patent metadata

Field	Value
Publication number	US-2017190693-A1
Application number	US-201715467737-A
Country	US
Kind code	A1
Filing date	Mar 23, 2017
Priority date	Oct 31, 2014
Publication date	Jul 6, 2017
Grant date	—

Abstract

The invention provides for compounds of formula (I)

wherein R 1 , X, Y, R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , m, and R″ have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

First claim

We claim:

1 . A compound:

or a pharmaceutically acceptable salt thereof.

2 . A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

3 . A method for treating cystic fibrosis in a subject comprising administering a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, to a subject in need thereof.

Assignees

• Abbvie S À R L
• Galapagos Nv

Inventors

• Altenbach Robert J
• Bogdan Andrew
• Greszler Stephen N
• Koenig John R
• Kym Philip R
• Liu Bo
• Searle Xenia B
• Voight Eric
• Wang Xueqing
• Yeung Ming C

Classifications

• A61K31/36

  Compounds containing methylenedioxyphenyl groups, e.g. sesamin · CPC title

• A61K31/4433

  containing a six-membered ring with oxygen as a ring hetero atom · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title

• C07D417/14

  containing three or more hetero rings · CPC title

• C07D491/052

  the oxygen-containing ring being six-membered · CPC title